The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan
Open Access
- 3 March 2003
- Vol. 97 (6), 1558-1563
- https://doi.org/10.1002/cncr.11191
Abstract
BACKGROUND Lung cancer is the leading cause of cancer death in Taiwan, and the paucity of dependable risk markers has impeded the early management of lung cancer. An association of human papillomavirus (HPV) 16/18 infection with lung cancer among nonsmoking Taiwanese women was revealed in our previous study. METHODS Nested PCR was employed to detect HPV 16/18 DNA in the blood circulation of 149 lung cancer patients and 174 noncancer controls. In addition, correlation of prevalence of HPV DNA between the blood circulation and lung tumor tissue was compared from 70 sets of paired tumor tissues and peripheral blood samples available. RESULTS The results showed that the prevalence rate of HPV 16/18 in the blood circulation of lung cancer cases was significantly higher than that of noncancer controls (47.7% vs. 12.6% for HPV 16, P < 0.0001; 30.9% vs. 5.2% for HPV 18, P < 0.0001). A significantly higher HPV 16 prevalence was detected in female lung cancer patients than that of male (57.6% vs. 41.1%, P = 0.048), as well as in cases with tumor Stages III/IV than those with tumor Stages I/II (54.6% vs. 29.3%, P = 0.006). After adjusting the effects of age, gender, and smoking status, a 6.5-fold greater risk of lung cancer was demonstrated for those subjects with HPV Type 16 positive (95% CI 3.7–11.3, P < 0.0001), a 9.2-fold for HPV Type 18 positive (95% CI 4.2–20.2, P < 0.0001), and a 75.7-fold greatest risk for those with both HPV Type 16 and 18 positive (95% CI 9.8–582.1, P < 0.0001). CONCLUSIONS These results suggested that the presence of HPV DNA in the blood circulation may serve as a feasible risk marker of lung cancer. Cancer 2003;97:1558–63. © 2003 American Cancer Society. DOI 10.1002/cncr.11191Keywords
This publication has 11 references indexed in Scilit:
- Viral load of human papillomavirus and risk of CIN3 or cervical cancerThe Lancet, 2002
- Low Incidence of HPV DNA in Sera of Pretreatment Cervical Cancer PatientsGynecologic Oncology, 2001
- Molecular genetic abnormalities in the pathogenesis of human lung cancerPathology and Oncology Research, 2001
- Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung in Okinawa, a subtropical island in southern JapanJournal of Clinical Pathology, 2000
- The Human Papillomavirus Type 16 E7 Oncogene Is Required for the Productive Stage of the Viral Life CycleJournal of Virology, 2000
- Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control studyThe Lancet, 2000
- Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control studyThe Lancet, 2000
- Human papillomavirus DNA in adenosquamous carcinoma of the lungJournal of Clinical Pathology, 1998
- Human papillomavirus DNA in squamous cell carcinoma of the lung.Journal of Clinical Pathology, 1996
- Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma.Thorax, 1996